Pharmacist Johanna Melin

Johanna Melin

Institute of Pharmacy

Clinical Pharmacy & Biochemistry

Freie Universität Berlin

Address Kelchstr. 31
Room 130A
12169 Berlin
Telephone 030-838 50662
Email johanna.melin[at]fu-berlin.de

Curriculum Vitae

 

 

since 04/2013 PhD student (Graduate Research Training Progam PharMetrX, Pharmacometrics & Computational Disease Modelling) at the Dept. of Clinical Pharmacy and Biochemistry supervised by Prof. Dr. Charlotte Kloft
08/2012 Registered as Pharmacist
02/2012-07/2012 Pre-registration Internship at Apotek Hjärtat Bellevuegarden (Malmö, Sweden)
08/2011-01/2012 Master thesis "Population Pharmacokinetic analysis of Atorvastatin and Rosuvastatin in critically ill patients with Sepsis" at the Therapeutics Research Center, School of Medicine, University of Queensland (Brisbane, Australia)
08/2006-08/2012 M. Sc. in Pharmaceutical Science at the University of Gothenburg (Gothenburg, Sweden)
08/2002-06/2005 High School/Gymnasium, Natural Science Program at Aranäsgymnasiet (Kungsbacka, Sweden)

Focus of research

 

[Forschungslinie 2]: Pharmacometric data analysis
 

“Pharmacokinetics of hydrocortisone in pediatric patients with congenital adrenal hyperplasia”

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders leading to decreased or no synthesis of cortisol. Low concentrations of cortisol leads to an imbalance in the steroid synthesis pathway, thereby, resulting in increased levels of androgens followed by symptoms, such as virilisation, hirsuitism and preoccus puberty. The prevalence of the more severe form is 1/15000 in newborns, but the less severe form is more prevalent (1/1000) and can sometimes be asymptomatic.

The recommended cortisol substitution therapy for growing paediatric patients constitutes of hydrocortisone. Drug monitoring in these patients may be problematic, since too high doses may increase the risk for Cushing’s syndrome, whereas too low doses may increase risk of adrenal crisis or disease progression. The therapeutic regimen is currently chosen based on empirical knowledge and is currently not standardised. We, therefore, see a need for improvement regarding the dosing regimen in this population to improve treatment outcome.

The aim of my PhD thesis will be to use a population-based pharmacokinetic approach to characterise the pharmacokinetics of hydrocortisone in paediatric patients from infants to adults. By relating the pharmacokinetics of hydrocortisone to disease-related biomarkers or patient characteristics, we hope to establish a pharmacokinetic-pharmacodynamic model, which later will be used in order to optimise therapy for paediatric patients with CAH.
The ultimate goal will be to establish a Therapeutic Drug Monitoring, which should be eval-
uated and optimally later could be used in the clinic.